Fagoo M, Braquet P, Robin J P, Esanu A, Godfraind T
Biochem Biophys Res Commun. 1986 Feb 13;134(3):1064-70. doi: 10.1016/0006-291x(86)90359-1.
Enterolactone, a lignan that has been identified in biological samples from man and several mammals, shares with ascorbic acid and cardiac glycosides a gamma-butyrolactone. It displaces 3H-ouabain from its binding sites on cardiac digitalis receptor and inhibits, dose dependently, the Na+, K+-ATPase activity of human and guinea-pig heart. The time dependence of this inhibition resembles that of dihydroouabain, a cardiac glycoside in which the lactone ring does not contain conjugated double bonds. The active concentrations of enterolactone as inhibitor of Na+,K+-ATPase are in the 10(-4) M range and, at those concentrations, the cross-reactivity with antidigoxin antibodies is low. Lignans may contribute to the putative digitalis-like activity found in tissues, blood and urine of several mammals including man.
肠内酯是一种在人类和多种哺乳动物的生物样本中已被鉴定出的木脂素，它与抗坏血酸和强心苷一样含有γ-丁内酯。它能从心脏洋地黄受体的结合位点上取代3H-哇巴因，并剂量依赖性地抑制人和豚鼠心脏的Na +，K + -ATP酶活性。这种抑制作用的时间依赖性类似于双氢哇巴因，双氢哇巴因是一种内酯环不含共轭双键的强心苷。作为Na +，K + -ATP酶抑制剂的肠内酯的活性浓度在10（-4）M范围内，在这些浓度下，其与地高辛抗体的交叉反应性较低。木脂素可能与在包括人类在内的多种哺乳动物的组织、血液和尿液中发现的假定洋地黄样活性有关。
